• Subscribe
  • Log In
  • Home
  • Daily Diary
  • Asset Class
    • U.S. Equity
    • Fixed Income
    • Global Equity
    • Commodities
    • Currencies
  • Sector
    • Basic Materials
    • Consumer Discretionary
    • Consumer Staples
    • Energy
    • Financial Services
    • Healthcare
    • Industrials
    • Real Estate
    • Technology
    • Telecom Services
    • Transportation
    • Utilities
  • Latest
    • Articles
    • Video
    • Columnist Conversations
    • Best Ideas
    • Stock of the Day
  • Street Notes
  • Authors
    • Doug Kass
    • Bruce Kamich
    • Jim Cramer
    • Jim "Rev Shark" DePorre
    • Helene Meisler
    • Jonathan Heller
    • - See All -
  • Options
  • RMPIA
  • Switch Product
    • Action Alerts PLUS
    • Quant Ratings
    • Real Money
    • Real Money Pro
    • Retirement
    • Stocks Under $10
    • TheStreet
    • Top Stocks
    • Trifecta Stocks
  1. Home
  2. / Investing
  3. / Healthcare

AbbVie Could Climb Even Higher

AbbVie prices are way above the rising 50-day moving average line.
By BRUCE KAMICH
Jan 29, 2018 | 08:58 AM EST
Stocks quotes in this article: ABBV

AbbVie Inc. (ABBV) was last reviewed back in the middle of September, when I suggested: "ABBV has gone 'vertical' on the daily chart, so there are considerable short-term profits built up. ABBV needs to catch its breath or correct a bit. A correction could be a sideways affair, or it could mean a pullback within an uptrend. I would favor taking some profits looking to rebuy ABBV after its correction has run its course."

Looking back at the price action since September, we can see (chart below) that prices did sell off into late September to briefly test the rising 50-day moving average line. Prices resumed their rally, and this month they have soared! What do the charts suggest now?

In this updated daily bar chart of ABBV, below, we can see that prices are way above the rising 50-day moving average line. ABBV is also well above the rising 200-day line.

In general, the pace of trading volume has increased since August and the On-Balance-Volume (OBV) line has risen to a new high to confirm the price action with aggressive volume. The trend-following Moving Average Convergence Divergence (MACD) oscillator is moving sharply higher, in a very bullish configuration.

In this weekly bar chart of ABBV, below, we can see a two-year sideways consolidation pattern around $60 before prices started a rally to double in less than a year.

ABBV is above the rising 40-week moving average line. The weekly OBV line has been rising since late 2016 and confirms the price advance with its own new high. The weekly MACD oscillator has been bullish since early 2017.

In this Point and Figure chart of ABBV, below, we can see the base pattern in the low $60s to mid-$50s. We can also see a upper level consolidation in the $90s. A $108 price target has been overshot, but there are no signs of selling or distribution.

Bottom line: ABBV has made a strong rally and has doubled from its base around $60. With no fresh Point and Figure price targets available at this time, I would suggest that a triple from the $60 base or $180 is the next possible upside price target. Longs should probably raise their sell stop protection to a close below $100.

Get an email alert each time I write an article for Real Money. Click the "+Follow" next to my byline to this article.

Employees of TheStreet are restricted from trading individual securities.

TAGS: Investing | U.S. Equity | Healthcare | Markets | How-to | Stocks

More from Healthcare

Emergent BioSolutions Turns Bearish, So Beware

Bruce Kamich
Mar 4, 2021 8:27 AM EST

A break in a key support level could precipitate further declines in the life sciences company's shares.

Centene Charts Remain Weak and Vulnerable

Bruce Kamich
Mar 3, 2021 1:35 PM EST

Let's review the charts and indicators.

Stopped Out on Johnson & Johnson but Willing to Buy it Lower

Bruce Kamich
Mar 3, 2021 12:20 PM EST

Stand aside for now.

Broad Rally, Vaccine Optimism, Johnson & Johnson, GameStop Roars, Trading Nvidia

Stephen Guilfoyle
Feb 25, 2021 7:04 AM EST

The market's catalyst had everything to do with the virus... optimism that humankind might stuff that scourge back into Pandora's box.

Eli Lilly Is Poised for a Pullback Before Renewed Longer-Term Gains

Bruce Kamich
Feb 23, 2021 7:43 AM EST

Let's review the charts and indicators.

Real Money's message boards are strictly for the open exchange of investment ideas among registered users. Any discussions or subjects off that topic or that do not promote this goal will be removed at the discretion of the site's moderators. Abusive, insensitive or threatening comments will not be tolerated and will be deleted. Thank you for your cooperation. If you have questions, please contact us here.

Email

CANCEL
SUBMIT

Email sent

Thank you, your email to has been sent successfully.

DONE

Oops!

We're sorry. There was a problem trying to send your email to .
Please contact customer support to let us know.

DONE

Please Join or Log In to Email Our Authors.

Email Real Money's Wall Street Pros for further analysis and insight

Already a Subscriber? Login

Columnist Conversation

  • 10:53 AM EST GARY BERMAN

    Nasdaq Composite: Some Backing and Filling Is Here

    As today is the 4th day of the month, it seems lik...
  • 07:59 AM EST PAUL PRICE

    Fabulous News on United Natural Foods (UNFI)

    The major potential risk factor for , its contrac...
  • 08:50 AM EST PAUL PRICE

    Michaels: Close to a Deal?

    It appears that a deal could be announced soon. ...
  • See More

COLUMNIST TWEETS

  • A Twitter List by realmoney
About Privacy Terms of Use

© 1996-2021 TheStreet, Inc., 225 Liberty Street, 27th Floor, New York, NY 10281

Need Help? Contact Customer Service

Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data & Company fundamental data provided by FactSet. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by FactSet Digital Solutions Group.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

FactSet calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.

Compare Brokers

Please Join or Log In to manage and receive alerts.

Follow Real Money's Wall Street Pros to receive real-time investing alerts

Already a Subscriber? Login